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ABSTRACT 
Topically applied drugs for the treatment of ocular inflammation are the most commonly used formulations due to many reasons: they are simple to 
use; they can be applied often and provide a high drug concentration; systemic side effects which are associated with oral administration can be 
avoided. But due to the physiological limitations of the eyes only a small number of anti-inflammatory agents, which have certain physico-chemical 
properties can be included in appropriate and efficient formulations for treatment of ocular inflammation. To prepare the optimal therapeutic and 
technological ophthalmic formulation, it is required to know the possibility of enhancing the bioavailability in the ocular tissues and to increase the 
therapeutic activity of the active substance, by using appropriate technological approaches to create a stable, tolerable and effective ophthalmic 
drug formulation. In this review, we focus on microemulsions, polymeric NPs, liposomes, SLNs, and nanosuspensions as formulations incorporating 
non-steroidal anti-inflammatory drugs (NSAIDs) for topical ophthalmic application.  
Keywords: NSAIDs, Nanoparticle-drug delivery systems, Topical ophthalmic administration.  
 
INTRODUCTION 
The various ophthalmic diseases are usually treated with topically 
administered drug formulations. Their disadvantage is the short 
time of contact with the eye, which leads to a low degree of 
absorption of the active substance [1]. This requires frequent 
administration, which usually leads to a high systemic exposure. 
These problems could be solved by looking for appropriate 
technological methods to increase the efficiency of the ophthalmic 
formulations. The strict requirements, which they must fulfill, are 
related to the specific sensitivity of the eye and its anatomical and 
physiological characteristics [2-5]. To prepare the optimal 
therapeutic and technological ophthalmic formulation, it is required 
to know the possibility of enhancing the bioavailability in the ocular 
tissues and to increase the therapeutic activity of the active 
substance, by using appropriate technological approaches to create a 
stable, tolerable and effective ophthalmic drug formulation [6-13]. 
Inflammation is a cellular and vascular response of the tissues to 
injury caused by physical or chemical agents, an invasion of 
pathogens, ischemia, excessive (hypersensitivity) or inadequate 
(autoimmune) functioning of the immune mechanisms. 
Inflammation facilitates the immune response and the subsequent 
removal of the antigenic material and the damaged tissue. From the 
moment the trauma is recognized by the organism, in the body start 
mechanisms for locating own and foreign substances and damaged 
tissues. The response is amplified by the activation of inflammatory 
cells and the production of chemical mediators such as acidic lipids-
prostaglandins, thromboxanes, leukotrienes, vasoactive amines, 
cytokines and others [14]. Acidic lipids are produced in the 
arachidonic cascade. Arachidonic acid is released from a phospho 
lipidic component of the cell membranes under the influence of 
phospholipase A2. The produced arachidonic acid takes 
cyclooxygenase or lipoxygenase pathway. The activation of the 
cyclooxygenase pathway leads to the formation of prostaglandins 
and thromboxanes, while the lipoxygenase pathway results in the 
production of eicosanoids and leukotrienes [14, 15]. The effects of 
the prostaglandins in the eyes are manifested in different ways [15, 
16]. They affect the intra ocular pressure: it can be increased by 
increasing the local vasodilatation and the water permeability 
(increased vascular permeability) or reduced by increasing the 
uveoscleral outflow. Furthermore, prostaglandins have an effect on 
the smooth muscles of the iris and cause miosis [15, 16]. 
Potent anti-inflammatory drugs are the corticosteroids and the 
NSAIDs. They have different mechanisms of action. Corticosteroids 
block the phospholipase A2 enzyme and inhibit the release of 
arachidonic acid. Thus, the production of all prostaglandins, 
thromboxanes and eicosanoids is suppressed [16]. On the other 
hand NSAIDs have an anti-inflammatory effect by inhibiting the 
enzyme cyclooxygenase (COX 1 and COX 2) [14, 15]. Using anti-
inflammatory drugs is a basic pharmacological approach for the 
treatment of inflammation. 
Topically applied drugs for the treatment of ocular inflammation are 
the most commonly used formulations due to many reasons: they 
are simple to use; they can be applied often and provide a high drug 
concentration; systemic side effects which are associated with oral 
administration can be avoided. But due to the physiological 
limitations of the eyes only a small number of anti-inflammatory 
agents, which have certain physico-chemical properties can be 
included in appropriate and efficient formulations for treatment of 
ocular inflammation. Corticosteroids are usually used as supporting 
agents for the topical treatment of ocular inflammation [17], but 
their potent anti-inflammatory effect is offset by serious side effects 
such as increased intraocular pressure, cataract progression, 
increased risk of infection and others [18]. NSAIDs have proven their 
safety and effectiveness and they are an alternative to corticosteroid 
therapy in the topical treatment of ocular inflammation [19]. 
Currently this therapeutic group has been widely used in topical 
formulations for the prevention of operational miosis, postoperative 
inflammation, treatment of seasonal allergic conjunctivitis, 
prevention and treatment of cystoid macular edema and for pain 
control after keratectomy [14, 15, 18, 19]. It has also been proved 
that NSAIDs are useful in the reduction of bacterial colonization on 
the lenses and that they participate in the prevention of bacterial 
adhesion on the epithelial cells of the cornea [20]. Although NSAIDs 
have a potent cyclooxygenase inhibitory activity their topical 
administration in ophthalmology is limited to the relatively water-
soluble indole acetic acid, aryl acetic acid, aryl propionic acid and 
derivatives of the enolic acid [21]. Most of the NSAIDs are drugs with 
weak acidic properties, which ionize at the pH of the tear fluid and 
thus have a limited permeability through the anionic cornea, which 
isoelectric point is 3.2 [2-4]. The production of formulations with 
lower values of pH increases the non-ionized fraction of the drug, 
improving the drug penetration. The lower pH also causes a 
discomfort for the patient due to irritation of the cornea and 
increased excretion of tear fluid. In addition, due to their anionic 
nature, NSAIDs are susceptible to forming insoluble complexes with 
the cationic quaternary ammonium preservatives such as 
benzalkonium chloride [6, 22]. These are major technological 
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problems and great challenges for the development of ophthalmic 
formulations. 
Topical route represents a safer administration. Therefore a major 
challenge to the scientists is to overcome the ocular barriers and 
reach the tissue target. In order, to overcome these problems, 
nanotechnology involving drug-loaded nanocarriers has been 
proposed as ophthalmic drug delivery systems that may control 
drug release and maintain therapeutic levels over a prolonged 
period of time. The success of nanocarriers for ocular drug delivery 
may depend on optimizing lipophilic-hydrophilic properties of the 
carrier-drug system, optimizing rates of biodegradation and safety. 
Polymers used for the preparation of nanocarriers should be 
mucoadhesive and biocompatible. The choice of polymer plays an 
important role in the release kinetics of the drug from a nanocarrier. 
Classification of NSAIDs 
NSAIDs is a heterogeneous group of compounds with different 
structural classes, which do not include a steroid nucleus derived 
biosynthetically from cholesterol in their chemical structure. Fig. 1 
shows the general chemical structure of NSAIDs [23].  
 
 
Fig. 1: General structure of NSAIDS 
 
A classification of some popular representatives from this medicine’s 
group according to their chemical structure is presented in table 1 
[23, 24]. The classification, based on selective/non-selective action 
towards COXs is popular and commonly used (table 2) [24]. The 
classification according to their chemical structure is used in this 
review. 
  
Table 1: Classification of some NSAIDs according to their chemical structure 
General chemical group Sub-group Representatives 
Carboxylic acids 
 
Salicylic Acids & Esters:  
Salicylates 
Acetylsalicylic Acid, Diflunisal, Choline Magnesium Trisalicylate, Sodium Salicylate, 
Olsalazine, Salsalate, Sulfasalazine 
Acetic Acids: Alkanones Nabumetone 
Acetic Acids:  
Phenylacetic Acids 
Diclofenac, Aceclofenac, Bromfenac 
Acetic Acids:  
Aryl and Hetero-aryl-
acetic Acids 
Indene and Indole Acetic Acids: Sulindac, Indomethacin, Etodolac;  
The Pyrrole Acetic Acids: Tolmetin, Ketorolac;  
Propionic Acid Derivatives Ibuprofen, Dexibuprofen, Fenoprofen, Carprofen, Flurbiprofen, Ketoprofen, 
Dexketoprofen, Naproxen, Loxoprofen, Oxaprozin 
Anthranilates Mefenamic Acid, Meclofenamate 
Enolic Acid derivatives Oxicams Piroxicam, Meloxicam, Tenoxicam, Droxicam, Lornoxicam 
Phenylpyrazolones Phenylbutazone, Oxyphenbutazone 
COX-2 Selective 
Inhibitors 
 Celecoxib, Rofecoxib, Valdecoxib, Etorixocib, Lumiracoxib, Firocoxib, Parecoxib 
Anilides  Acetaminophen, Phenacetin 
Sulfonanilides  Nimesulid 
Some of the drugs shown in table 1 have not yet found application in ophthalmology. Poor aqueous solubility, stability of the drug, a low degree of 
absorption and irritating effect on the cornea are some of the reasons. 
 
Table 2: Classification of some NSAIDs according to their COXs selectivity 
Selectivity Drugs 
Weak COX inhibitors Choline Magnesium Trisalicylate, Sodium Salicylate, Olsalazine, Salsalate, Sulfasalazine 
COX-1/COX-2 
inhibitors 
Piroxicam, Sulindac, Indomethacin, Tolmetin, Ketorolac, Ibuprofen, Dexibuprofen, Fenoprofen, Carprofen, Flurbiprofen, 






Celecoxib, Rofecoxib, Valdecoxib, Etorixocib, Lumiracoxib, Firocoxib, Parecoxib 
COX-3 inhibitors Acetaminophen 
NSAID-loaded nano-and microcarriers for topical ophthalmic administration 
 
Carboxylic acids 
Salicylic acids and esters 
Acetylsalicylic acid (ASA) is the main representative of the sub-group 
of the salicylic acids and their esters. ASA (2-acetoxybenzoic acid) is 
slightly soluble in water and freely soluble in alcohol [6, 22]. By 
varying ASA: albumin ratios from 0.06 to 1.0 stable ASA loaded 
albumin nanoparticles (NPs) have been obtained by coacervation. The 
NPs were with sizes from 46.8 nm to 190.8 nm respectively and had 
low polydispersity. NP formulations have released ASA at a sustained 
rate for prolonged duration (50% total cumulative percentage at the 
end of 20 hrs, 90% at 72 hrs). Thus produced NPs could be applied as 
intraocular release agents for diabetic retinopathy [25]. 
Acetic acids 
The main representatives of this sub-group, which find application 
in topical ophthalmic formulations, are derivatives of phenylacetic 
acids and carbo-and hetero-cyclic acetic acids.  
i) Phenylacetic acids 
Diclofenac (2-(2,6-dichloranilino) phenylacetic acid) is an aryl-acetic 
acid derivative in the group of NSAIDs. It is mainly employed for the 
inhibition of intraoperative miosis and post-operative acute and 
chronic nonbacterial inflammations of the anterior part of the eyes 
in cataract surgery. Diclofenac is used as either the sodium or 
potassium salt [6, 22]. 
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Agnihorti et al. have prepared polymeric NP suspensions from poly 
(lactide-co-glycolide) and poly(lactide-co-glycolide-leucine) loaded 
with diclofenac sodium (DS), with the aim of improving the ocular 
availability of the drug [26]. The NP system has shown an interesting 
size distribution suitable for ophthalmic application. Polymer NPs 
seemed to be devoid of any irritant effect on cornea, iris and 
conjunctiva for as long as 24 hours after application according to the 
modified Draize test. In- vitro release tests have shown an extended-
release profile of DS from the NPs. Thus apparently the NP 
suspensions from poly (lactide-co-glycolide) and poly (lactide-co-
glycolide-leucine) polymers are suitable inert carrier for ophthalmic 
drug delivery of DS. 
Ahuja et al. [27] have studied the influence of the pharmaceutical 
factors on the absorption of diclofenac from an experimental model 
and from an aqueous ophthalmic formulation which is commercially 
available, using cornea from goat. 
Solid lipid NPs (SLNs) have been prepared with a combination of 
homolipid from goat (goat fat) and phospholipid, and evaluated for 
DS delivery to the eye using bio-engineered human cornea, produced 
from immortalized human corneal endothelial cells (HENC), stromal 
fibroblasts and epithelial cells CEPI 17 CL 4 [28]. Encapsulation 
efficiency has been high and sustained release of DS and high 
permeation through the bio-engineered cornea has been achieved. 
Results obtained by Attama et al. have shown that permeation of DS 
through the cornea construct has been improved by formulation as 
SLN modified with phospholipid. 
Also enhancement in ocular delivery of DS and sustained drug 
release for 6 h in vitro have been achieved with DS loaded SLNs 
using a microemulsion technique [29].  
DS-loaded Eudragit RS 100-based nanosuspensions have been 
fabricated by employing oil-in-water emulsion solvent evaporation 
technique [30]. The prepared NPs have revealed a mean particle size 
in a narrow range of 145.2 to 215.3 nm, high values of the zeta 
potential (ZP) of+32.6 to+49.6 mV, and also high drug entrapment 
efficiency in the range of 64.55% to 98.50%. The nanosuspensions 
have been observed to provide sustained in vitro drug release 
behaviour.  
The absence of irritation towards the ocular structures has been 
verified by applying placebo nanosuspensions to the rabbit eye and a 
modified Draize test has been performed. Polymeric NPs seemed to be 
devoid of any irritant effect on cornea, iris and conjunctiva for as long 
as 24 hrs after application. It has been observed that the drug release 
have matrix diffusion controlled and the release mechanism was non-
Fickian. Eudragit RS 100 nanosuspensions loaded with DS may 
represent an efficacious vehicle for controlled ophthalmic delivery.  
In another study, the ocusert has been prepared as membrane 
permeation controlled devices with the drug loading sufficient 
enough for ‘Once a day’ therapy. DS ocusert has been prepared using 
the polymers hydroxy propyl methyl cellulose (HPMC) and hydroxy 
propyl cellulose (HPC) and dibutyl phthalate (DBP) as plasticizer by 
solvent casting technique [31]. The prepared DS ocusert (thickness 
0.217 mm, weight uniformity 21.53 mg, and drug content about 0.25 
mg) has shown prolonged zero order release and increased contact 
time. The rabbit eyes subjected to ocular toxicity test have not 
shown any signs of irritations or inflammations. 
In a similar study ocular inserts of DS using different polymers such as 
HPMC, Eudragit L100 at various concentrations and combinations using 
DBP as plasticizer have been prepared [32]. The optimized formulation 
has shown anomalous diffusion predominantly with first order kinetics.  
These are just some of the many examples in the literature which 
show conclusively that the incorporation of diclofenac into various 
carriers such as polymer NPs, SLNs, nanosuspensions or intraocular 
inserts could lead to increased contact time, high permeation 
through the cornea and provide sustained in vitro drug release 
behaviour, without any signs of ocular toxicity.  
Aceclofenac (2-[2-[2-(2,6-dichlorophenyl)amino]phenyl]acetyl] oxy 
acetic acid) is the glycolic acid ester of diclofenac. 
Aceclofenac loaded PLGA NPs were prepared by spontaneous 
emulsification solvent diffusion method (SESD) [33]. In-vitro release 
studies in phosphate buffer (pH 7.4) showed extended drug release 
and fitted the theoretical target release profile. Most formulations 
exhibited Fickian diffusion drug release profiles. The optimized 
formulation, prepared using 94.07 mg aceclofenac, 400 mg 
poly(lactic-co-glycolic acid) (PLGA) and 4.72% poly(vinyl alcohol) 
(PVA), had entrapment efficiency 67.72%, a mean particle size of 
593 nm and exhibited a prolonged release (t50%=5.23 h). 
The SLN gel formulations of the dispersions were compared to the 
SLN dispersions and with the marketed gel of aceclofenac [34]. The 
SLNs were prepared by high speed homogenization and ultra-
sonication method with the fixed amount of aceclofenac (10%) and 
pluronic F68 (1.5%). Permeation rate and controlled release 
property of xanthan gum loaded SLN gel formulations and SLN 
dispersion was studied through excised pig skin for 24 hrs. The drug 
release of SLN gel formulations was better controlled as compare to 
SLN dispersions. In vivo anti-inflammatory study showed that the 
action of aceclofenac was enhanced through SLN dispersion and gel 
formulations.  
Eudragit RL 100-based NPs of aceclofenac obtained by 
nanoprecipitation have shown sustained in vitro drug release which 
followed the Higuchi square-root kinetics [35]. In the in 
vitro permeation study, the NP formulation showed 2-fold higher 
permeation of the drug through excised cornea compared to an 
aqueous solution of the drug with no signs of corneal damage. The in 
vivo studies involving arachidonic acid-induced ocular inflammation 
in rabbits revealed significantly higher inhibition of 
polymorphonuclear leukocytes migration (p<0.05) and lid closure 
scores by the NP formulation compared with the aqueous solution. 
The formulation was quite stable to ensure two year shelf life at 
room temperature. 
Bromfenac is another representative of this group. The high degree 
of penetration and potency of bromfenac can be attributed to the 
halogenation of the molecule: by adding a bromine moiety the 
NSAIDs becomes highly lipophilic which allows rapid, sustained 
drug levels in the ocular tissues. 
Bromfenac encapsulated chitosan/sodium alginate mucoadhesive 
NPs for sustained ocular application, optimized using experiments 
by employing a 3-factor, 3-level Box-Behnken statistical design, have 
exhibited a biphasic drug release profile with an initial burst 
followed by a very slow drug release [36]. The ocular 
pharmacokinetics of NPs and marketed formulation has been 
evaluated in rabbits. The NPs exhibited significant mucin adhesion. 
In comparison to the marketed suspension, the NP formulation has 
exhibited significant enhancement of AUC (0−∞) (~4.02-fold) and 
clearance has been significantly decreased (~5.5-fold). Thus, 
mucoadhesive bromfenac-loaded chitosan/alginate NPs could be 
considered useful approach aiming to sustained ocular residence 
and reduce dosing frequency. 
In another study microspheric in-situ gel for ocular drug delivery 
system of bromefanac sodium has been prepared [37] for the 
treatment of post-operative cataract surgery. The microspheric in-
situ gel of optimized formulation has shown drug release of 77.989% 
at the end of 24 hrs. Eye irritancy test has performed on albino 
rabbits. The results of the ocular irritation studies have indicated 
that the formulation have been non-irritant. The stability data 
recorded over a 3 months period according to ICH guidelines have 
observed that formulations have been stable. Hence, it could be 
concluded that microsphere in-situ gels are a viable alternative to 
conventional eye drops by providing sustained release of 
medicaments in the eye. 
There are some NSAIDs approved by the FDA for the treatment of 
post-operative inflammation after cataract surgery (ketorolac, 
flurbiprofen, bromfenac, diclofenac and nepafenac). Nepafenac is the 
only nonsteroidal anti-inflammatory prodrug that requires 
conversion to its active form, amfenac, through intraocular 
enzymatic hydrolysis [38]. In a clinical study comparing aqueous 
humor concentrations of four NSAIDs after administration in 
patients having cataract surgery, nepafenac showed significantly 
greater ocular bioavailability than the others [39]. 
Peneva  
Int J Pharm Pharm Sci, Vol 7, Issue 9, 13-19 
16 
ii) Carbo-and hetero-cyclic acetic acids 
Indomethacin and ketorolac are the most studied representatives of 
this group for inclusion in nanocarriers for eye administration.  
Indomethacin (IMC), 2-{1-[(4-Chlorophenyl) carbonyl]-5-methoxy-
2-methyl-1H-indol-3-yl} acetic acid, is used in ophthalmology as an 
aqueous solution of sodium salt and tromethamine salt [6, 22]. It is 
practically insoluble in water, unstable in alkaline medium and 
poorly soluble in acidic medium. IMC can be used topically in eye 
drops with concentration from 0.1% to 1% (w/v) for the prevention 
of miosis during cataract surgery and for cystoid macular edema 
prevention [6, 22]. 
To overcome the technological problems associated with the 
insolubility and the instability of IMC in an aqueous medium and its 
low bioavailability after topical administration, several models of 
drug delivery systems have been developed and studied.  
Poly (ε-caprolacton) NPs, nanocapsules and lecithin nanoemulsions 
with IMC with an average size of 225 nm, obtained by surface 
deposition, nanoprecipitation and spontaneous emulsification have 
been studied. In vitro comparison between colloidal carriers and 
commercial eye drops has shown a threefold higher concentration of 
the drug from the colloidal systems. Moreover, in vivo assessment of 
these colloidal systems in rabbit’s eyes has shown three fold higher 
concentration of IMC in the aqueous humor 0.5 hrs after 
administration and 300% increase in drug availability compared to 
commercial formulations [40]. 
Furthermore, chitosan coated poly (ε-caprolacton) NPs with IMC 
have demonstrated a twofold increase in the ocular bioavailability 
[41]. In another study, an IMC-chitosan-nanoemulsion has shown 
more efficient healing of corneal chemical ulcer compared to NPs 
preparation and the high level of IMC in inner ocular structure 
thereby increasing drug delivery efficiency [42]. 
Chetoni et al. [43] have developed a model of an aqueous solution of 
IMC (0.1%, w/v). Poloxamer-407 was used as a co-solvent. The 
solution was stable and showed a higher level in the aqueous humor 
and faster disappearance of the inflammation symptoms in a model 
of immunogenic uveitis compared to the commercial formulation. 
Andonova et al. have demonstrated for the first time the possibility 
of an effective in-situ incorporation of IMC into homopolymer 
poly(vinyl acetate) (pVAc) and polystirene NPs and NPs of 
copolymers of vinyl acetate (VAc) with 3-dimethyl 
(methacryloyloxyethyl) aminopropyl sulfonate (DMAPS) (p (VAc-co-
DMAPS)) as well as mixtures of NPs of these polymers with the 
hydrophilic chitosan, Carbopol® and p(DMAPS) by one-stage 
emulsion polymerization without using an emulsifier [44-47]. The 
rate and degree of release of IMC from these nanosized polymer 
carriers included in ophthalmic formulations could be adjusted by 
the composition of the copolymers of the polymer mixtures, as well 
as the conditions for the preparation of the NPs. The established 
biocompatibility of pVAc [48], the stabilizing role on the in-situ 
included IMC [49] and the research on its release from nanosized 
carrier at pH 7.4, have given grounds for the authors to recommend 
the NPs from pVAc homo-and copolymers and their mixtures with 
hydrophilic and biocompatible chitosan, Carbopol ® and p (DMAPS) 
as a drug delivery system in ophthalmic formulations [50, 51]. 
An ophthalmic solution of ketorolac is available and is used to treat 
eye pain and to relieve the itchiness and burning of seasonal 
allergies. The ophthalmic formulation could be used in cases where a 
raised intraocular pressure (glaucoma) is to be avoided [22]. 
Ketorolac ((±)-5-benzoyl-2,3-dihydro-<brF/>1H-pyrrolizine-1-
carboxylic acid) is an isostere of ketoprofen, more precisely, it is a 
dihydro pyrrolizine carboxylic acid derivative structurally related to 
indomethacin. Ketorolac loaded chitosan NPs have been obtained by 
ionic-co-precipitation technique. The drug loading-release studies 
have been very promising for an alternative to treat ocular diseases 
such as pseudophakic cystoid macular edema according to the 
obtained data [52]. 
Moreover, ketorolac has been successfully entrapped in polymeric 
micelles made of copolymer of N-isopropylacrylamide (NIPAAM), 
vinyl pyrolidone (VP) and acrylic acid (AA) having cross-linkage 
with N,N′-methylene bis-acrylamide (MBA). The NP formulations 
with an average diameter of 35 nm at 25 °C and drug entrapment 
about 80% have been stable for 8-10 days at room temperature. The 
drug release in aqueous buffer (pH 7.2) from the polymeric micelles 
at 25 °C has been 20% and 60% after 2 and 8 hrs respectively and 
has been temperature and pH dependent. In vitro corneal 
permeation studies through excised rabbit cornea have indicated a 
twofold increase in the ocular availability with no corneal damage 
compared to an aqueous suspension containing the same amount of 
drug as in the NPs. The formulation has shown significant inhibition 
of lid closure up to 3 hrs and PMN migration up to 5 hrs compared to 
the suspension containing non-entrapped drug, which did not show 
any significant effect [53]. 
Propionic acids 
Flurbiprofen ((RS)-2-(2-fluorobiphenyl-4-yl) propanoic acid), 
ibuprofen ((RS)-2-(4-(2-methylpropyl) phenyl) propanoic acid) and 
naproxen ((+)-(S)-2-(6-methoxynaphthalen-2-yl) propanoic acid) 
are the exploited members of this group for inclusion in NPs as drug 
delivery systems in ophthalmic formulations.  
Poly (D,L-lactide-co-glycolide) nanospheres with incorporated 
flurbiprofen have been prepared by the solvent displacement 
technique for the purpose of assessing drug-polymer 
physicochemical interactions, flurbiprofen release from the polymer 
matrix and eye permeation of the drug formulated in the colloidal 
system [54]. The ex vivo corneal permeation study has shown that 
flurbiprofen-loaded nanospheres enhanced drug penetration by 
about twofold over commercial eye drops containing PVA and by 
about fourfold over flurbiprofen in pH 7.4 phosphate buffer. The 
corneal hydration level of each cornea has been determined in order 
to evaluate potential corneal damage. 
Flurbiprofen has been also included in Eudragit RS 100® and 
Eudragit RL 100® for prevention of miosis during extracapsular 
cataract surgery [55]. The drug included in these polymers has 
shown prolonged release and increased bioavailability. 
Moreover, flurbiprofen has been successful included in 
nanostructured lipid carriers. Gonzales-Mira et al. have implemented 
a 24 full factorial design based on 4 independent variables to plan 
the experiments, namely, the percentage of stearic acids with regard 
to the total lipid, the flurbiprofen concentration, the stabilizer 
concentration, and the storage conditions (i.e. storage temperature) 
[56]. Optimization of the process has been achieved and the best 
formulation corresponded to the nanostructured lipid carriers 
formulation composed of 0.05 (wt %) flurbiprofen, 1.6 (wt %) 
Tween® 80 and a 50:50 ratio of stearic acid to castor oil, with an 
average diameter of 288 nm, polydispersity index (PI) 0.245 and 
zeta-potential (ZP) of −29  mV. The developed systems have shown 
physico-chemical stability with high tolerance after ophthalmic 
application. 
With the aim of improving the availability of sodium ibuprofen at 
intraocular level, ibuprofen-loaded polymeric NP suspensions have 
been made from Eudragit RS 100 [57]. In vitro dissolution tests have 
indicated a controlled release profile of ibuprofen from NPs. In vivo 
efficacy has been assessed on rabbit’s eye after induction of an 
ocular trauma (paracentesis). An inhibition of the miotic response to 
the surgical trauma has been achieved, comparable to a control 
aqueous eye-drop formulation, even though a lower concentration of 
free drug in the conjunctival sac has been reached from the NP 
system. Drug levels in the aqueous humour have been also higher 
after application of the nanosuspensions. The NPs did not show any 
damage to the ocular tissues and thus these polymers have proven 
to be inert carriers. 
Ibuprofen nanostructured lipid carriers (NLCs) have been prepared 
by melted-ultrasonic methods; gelucire 44/14 has been selected as 
one of the solid lipid matrix materials due to the good particle size 
dispersion and excellent contribution to the corneal permeability of 
the model drug [58]. The corresponding apparent permeability 
coefficients (P (app)) have been 1.28 and 1.36 times higher than that 
of the control preparation. Ibuprofen NLCs have displayed 
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controlled-release properties. The AUC of the optimized formulation 
of ibuprofen NLCs has been 3.99 times greater than that of ibuprofen 
eye drops.  
The NPs of naproxen with Eudragit RS 100 have been formulated 
using the solvent evaporation/extraction technique (the single 
emulsion technique) [59]. The effect of several process parameters 
i.e. drug/polymer ratio, aqueous phase volume and speed of 
homogenization on the size of the nanoformulations has been 
considered. All the prepared formulations using Eudragit RS 100 
have resulted in nano-range size particles with relatively spherical 
smooth morphology. The NPs have displayed a slowed release 
pattern with the reduced burst release in comparison with the intact 
drug powder and the physical mixtures of drug and polymer. 
According to these findings, the formulation of naproxen-Eudragit 
RS 100 NPs has been able to improve the physicochemical 
characteristics of the drug and possibly could increase the anti-
inflammatory effects of the drug following its ocular or intra-joint 
administration. 
Javadzadeh et al. formulated NPs of naproxen with PLGA using single 
emulsion technique [60]. Drug/polymer ratio, aqueous phase 
volume and speed of homogenization have been considered as 
process parameters to achieve optimal preparation conditions. The 
study suggested the feasibility of formulating NPs of PLGA with 
satisfactory physicochemical characteristics and increasing the anti-
inflammatory effects of the drug following its ocular or intra-joint 
administration. 
Enolic acids 
The derivatives of enolic acid are subdivided into pyrazolones and 
oxicams according to their structure. Piroxicam (4-hydroxy-2-
methyl-N-(2-pyridinyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-
dioxide) is the main representative of the oxicams sub-group 
included in nanocarriers as drug delivery systems in topical eye 
formulations. 
To investigate the anti-inflammatory impact of piroxicam 
nanosuspension, Eudragit RS100 nanoformulations have been used 
to control inflammatory symptoms in rabbits with endotoxin-
induced uveitis (EIU). The NPs of piroxicam: Eudragit RS100 has 
been formulated using the solvent evaporation/extraction 
technique. Kinetically, the release profiles of piroxicam from NPs 
appeared to best fit the Weibull model and diffusion has been the 
superior phenomenon. The in vivo examinations have revealed that 
the inflammation could be inhibited by the drug: polymer 
nanosuspension more significantly than the microsuspension of the 
drug alone in rabbits with EIU. Upon these findings, the authors have 
proposed that the piroxicam: Eudragit RS100 nanosuspensions may 
be considered as an improved ocular delivery system for local 
inhibition of inflammation [61]. 
Piroxicam-loaded pectin microspheres have been prepared by a 
spray-drying technique [62]. Piroxicam loaded in the pectin 
microspheres has shown a faster in vitro dissolution rate compared 
to solid micronized drug. The precorneal retention of fluorescein-
loaded microspheres has been evaluated in vivo in albino rabbits. An 
aqueous dispersion of fluorescent microspheres has shown a 
significantly increased residence time in the eye (2.5 vs. 0.5 hr) 
when compared to a fluorescein solution. In vivo tests in rabbits of 
dispersions of piroxicam-loaded microspheres have also indicated a 
significant improvement of the drug bioavailability in the aqueous 
humour (2.5-fold) when compared to commercial piroxicam eye 
drops.  
Cox II Inhibitors 
Celecoxib and valdecoxib are the representatives of the group of 
Cox-II inhibitors. A challenge is to improve the dissolution rate of 
drugs and thus to optimize the bioavailability in the ocular tissues. 
Data on the inclusion of meloxicam in nanocarriers as drug delivery 
systems in topical eye formulations were not found.  
Several celecoxib-loaded NPs have been prepared by emulsification 
solvent diffusion technique using different polymers including 
chitosan, sodium alginate, PCL, PLA and PLGA [63, 64]. In one of the 
studies, selected preparations have been loaded with celecoxib and 
incorporated in three different ophthalmic preparations (eye drops, 
in-situ gelling system and gel) [64]. In vitro release of celecoxib from 
different ophthalmic formulations has been sustained over a period 
of 24 hrs and belonged to non-Fickian Higuchi diffusion model. A 
cytotoxicity experiment has shown that the tested formulations are 
biologically safe and non-toxic. Gels containing celecoxib-loaded 
PCL-NPs and chitosan-NPs have proven to be the most physically 
and chemically stable formulations which determined the in vivo 
study in order to evaluate the ocular bioavailability of celecoxib in 
NP-loaded ophthalmic formulations. Gels containing NPs have 
shown a higher ocular bioavailability than the control preparation 
which indicated higher AUC0-24, AUC0-∞ and Cmax values and several 
folds increase in the relative bioavailability. These formulations have 
also shown more extended release of celecoxib that lasts for more 
than one day. The gel containing chitosan-NPs has had a higher 
bioavailability and more extended release of the drug than those 
containing PCL-NPs due to the bio adhesiveness and penetration 
enhancement of the polymer. 
In an attempt to improve ocular bioavailability, NP formulation of 
valdecoxib with HP β CD has been evaluated [65]. As anticipated, 
levels of valdecoxib in the cornea and conjunctiva have been 
significantly higher in NP-treated rabbit’s eyes compared to control. 
CONCLUSION 
The nano carriers applied as ocular drug delivery systems offer 
undoubted advantages such as higher solubility, higher area 
available for dissolution and higher dissolution rate. Another 
advantage of the nano systems is the higher corneal penetration. 
They could combine ophthalmic prolonged action with the ease of 
the application of liquid eye drops. They could offer a high stability 
of the drug, protecting it from the negative environmental impact 
and also provide controlled release and target action. Ophthalmic 
drug delivery may benefit to a full extent from the characteristics of 
nano-sized drug particles. In conclusion, a multi-disciplinary 
approach from pharmacology to ophthalmology and from 
biomaterial science to pharmaceutical science will bring to clinical 
use these innovative NSAIDs-loaded nano systems for the 
pharmacological management of sight-threatening eye diseases. 
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